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Incidence and epidemiology
Primary bone tumours are rare, accounting for < 0.2% of malig-
nant neoplasms registered in the EUROCARE (European Cancer
Registry based study on survival and care of cancer patients) data-
base [1]. Different bone tumour subtypes have distinct patterns of
incidence, and each has no more than 0.3 incident cases per
100 000 per year. Osteosarcoma (OS) and Ewing sarcoma (ES)
have a relatively high incidence in the second decade of life, where-
as chondrosarcoma (CS) is more common in older age [2–4].
OS is the first primary cancer of bone (incidence: 0.3 per
100 000 per year). The incidence is higher in adolescents (0.8–1.1
per 100 000 per year at age 15–19 years) [2–3]. The male to female
ratio is 1.4:1. Most OSs of younger patients arise in an extremity,
while the proportion of axial tumour sites increases with age.
Risk factors for the occurrence of OS include previous radiother-
apy (RT), Paget disease of bone and germline genetic abnormal-
ities associated with Li–Fraumeni syndrome, Werner syndrome,
Rothmund–Thomson syndrome, Bloom syndrome and heredi-
tary retinoblastoma [5].
CS is the most frequent bone sarcoma of adulthood. The inci-
dence is 0.2 per 100 000 per year, with a median age at diagno-
sis between 30 and 60 years. No gender predominance has been
reported [2–4, 6].
ES is the third most common primary malignant bone tumour.
It occurs most frequently in children and adolescents, but is also
seen in adults. Median age at diagnosis is 15 years and there is a
male predominance (1.5:1). In white Caucasians > 25 years old,
ES has an incidence of 0.3 per 100 000 per year [1–4], and it is
even rarer in the African and Asian population. The genetic basis
for the difference between ethnical groups has been recently
linked to a common genomic germline variant, which extends a
microsatellite, thereby facilitating the binding of the EWSR1–
FLI1 chimeric protein to the EGR2 gene locus, leading to higher
expression of the transcription factor early growth response 2
(EGR2) and increased susceptibility to ES [7]. The most common
ES primary sites are the extremity bones (50% of all cases), fol-
lowed by pelvis, ribs and vertebra. However, any bone can poten-
tially be affected and a soft tissue origin is also possible, especially
in adults (30% of cases).
Chordomas are even rarer compared with other subtypes, with
an incidence of 0.5 per million per year [1–4].
High-grade spindle/pleomorphic sarcomas of bone are a
heterogeneous group of primary malignant bone tumours that do
not fulfil the histological criteria for a diagnosis of OS, CS or ES [8].
Giant cell tumour (GCT) of bone is a benign, locally aggressive
and rarely metastatic intramedullary bone tumour composed of
mononuclear cells and osteoclast-like multinucleated giant cells,
with a variable and unpredictable potential for aggressive growth.
It represents  5% of primary bone tumours, with an incidence
of approximately 1 per million per year [9].
Diagnosis and pathology/molecular biology
A general diagnostic strategy for bone sarcomas is shown in
Figure 1. The medical history should focus on characteristic
symptoms such as duration, intensity and timing of pain. The
presence of persistent non-mechanical bone pain, predominantly
at night, should prompt a radiological assessment. Swelling and
functional impairment can be present if the tumour has pro-
gressed through the cortex and distended the periosteum, but
they are often later signs. The differential diagnosis of a bone sar-
coma includes osteomyelitis, benign tumours and bone metasta-
ses, all of which outnumber primary bone sarcomas [10–12]. The
diagnosis can be strongly oriented by patient age. For patients
< 5 years old, a destructive bone lesion could be interpreted pre-
dominantly as either metastatic neuroblastoma or Langerhans
cell histiocytosis (LCH). For patients aged 5 years old, the like-
lihood of a primary bone sarcoma is higher. In adult patients,
after 40 years of age, bone metastases and myeloma are the most
common diagnoses [12].
Conventional radiograph in two planes is the first radiological
investigation. When the diagnosis of malignancy cannot be
excluded with certainty on radiographs, the next step should be
magnetic resonance imaging (MRI) of the whole compartment
with adjacent joints, which is regarded today as the best modality
for local staging of extremity and pelvic tumours [13]. Computed
tomography (CT) may provide additional information by allow-
ing a better visualisation of calcifications, periosteal bone forma-
tion and cortical destruction. It is generally the imaging modality
of choice of other primary sites.
All patients with a bone lesion that is likely to be a primary ma-
lignant bone tumour on a radiological basis should be referred to
a bone sarcoma centre or to an institution belonging to a special-
ised sarcoma network [14–15]. Children and adolescents should
be referred to centres which in addition provide age-specific ex-
pertise. The biopsy and the pathological diagnosis require expert-
ise in the field and should be discussed in a multidisciplinary
setting.
The biopsy of a suspected primary malignant bone tumour
should be carried out at the reference centre for bone sarcomas,
with a primary biopsy under the supervision of a surgical team
who will carry out the definitive tumour resection or by a dedi-
cated interventional radiologist [14–17]. In most patients, a core-
needle biopsy, taken under imaging control, can be an appropri-
ate alternative to open biopsy. Contamination of surrounding tis-
sue should be minimised, and adequate multiple sampling of
representative areas must always be provided. The biopsy ap-
proach and area of tumour to be sampled are pre-determined
after multidisciplinary review of imaging. If osteomyelitis is a dif-
ferential diagnosis, samples should be sent for microbiological
culture. If required, an open biopsy should be carried out using a
longitudinal incision. In aggressive and malignant tumours of
bone, the biopsy tract and the channels through which drains
have been placed must be considered to be potentially contami-
nated and must later be removed, together with the resection spe-
cimen, in an effort to minimise the risk of a local recurrence.
Therefore, biopsy tracts should be clearly marked by means of a
small incision or an ink tattoo to ensure that the location is recog-
nised at the time of the definitive procedure. In case of spinal col-
umn involvement, laminectomy or decompression should be
avoided unless necessary to relieve spinal cord compression, and
tissue sampling must be carried out whenever a bone sarcoma is
suspected.
Samples must be interpreted by an experienced bone sarcoma
pathologist, in collaboration with the radiologist, and discussed
in a multidisciplinary team. The request form should be
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completed with all details that might be relevant for diagnosis,
including patient’s age, the site of the tumour, radiological find-
ings, presence of multiple lesions, family history and preoperative
treatments for surgical specimens.
With the increasing capability for accurate molecular diagnosis
and next-generation sequencing (NGS) technologies, samples
should be quickly submitted for pathological assessment. The
collection of fresh frozen tissue is strongly encouraged, to enable
molecular diagnostics. As an alternative, decalcification in ethyle-
nediaminetetraacetic acid (EDTA) instead of methanoic acid can
be considered. Tumour imprints (touch preparations) are used
by some, but not all, expert institutions: they might be useful for
tumour-specific translocation by fluorescent in situ hybridisation
(FISH) in some institutions. Informed consent for tumour bank-
ing should be routinely sought as for all rare malignancies, ena-
bling later analyses for research, depending on local regulations.
The nature of the bone specimen received for pathology
reporting should be recorded, i.e. needle biopsy, curettage or ex-
cision (e.g. segmental resection, limb salvage amputation, or an-
other complex resection, such as a hemipelvectomy). It is usually
necessary to decalcify the bone tumour biopsy using specific
standard operating procedures. The histological features of the
tumour should be described and the tumour type (and subtype)
specified according to the most recent version of the World
Health Organization (WHO) classification [18, 19]. The results
of relevant ancillary investigations (e.g. immunohistochemistry
or molecular assessments) should be accurately recorded.
Molecular diagnostic techniques currently available include
FISH, reverse transcription-polymerase chain reaction (RT-
PCR) and NGS technologies. Examples include translocation de-
tection in ES and mesenchymal CS, isocitrate dehydrogenase
(IDH1 and IDH2) mutations in conventional CS and MDM2
amplification in parosteal and intramedullary low-grade OS.
At the time of the resection of the primary tumour, the size of
the tumour in the resected bone should be recorded (three-
dimensional measurement in mm) [19, 20]. The pathology re-
port should also describe the extent of local tumour spread,
including involvement of specific anatomical soft tissue and bone
compartments. It should be recorded whether the resection mar-
gins are either clear or infiltrated and the distance of tumour
from the nearest resection margin measured (in mm).
Photographs should be taken of the intact specimen and of the
tumour slabs after sawing. A complete, representative slab of the
tumour, usually in the longitudinal axis as guided by the radio-
logical images, should be embedded in a grid manner for micros-
copy. This is especially relevant after neoadjuvant chemotherapy
(ChT) to assess response. The tumour should be coded using
Systematic Nomenclature of Medicine (SNOMED) or
International Classification of Diseases for Oncology (ICD-O)
codes.
Staging and risk assessment
All new cases of bone tumours should be formally discussed in a
multidisciplinary team at a bone sarcoma reference centre with
the radiologist, the pathologist, the surgeon, the radiation
oncologist and the medical and/or paediatric oncologist. The
output of the multidisciplinary discussion must be recorded.
Several staging systems for bone tumours are in use [20–22].
However, none of them is perfect or generally accepted. Tumour
burden (volume) and the presence of detectable metastases are
the two main factors that are taken into consideration in the clin-
ical staging of these diseases. General staging should be carried
out to assess the extent of distant disease, including bone scintig-
raphy, chest radiographs and CT [23]. Whole-body MRI and
positron emission tomography (PET)-CT or PET-MRI are in-
creasingly used for staging (including detection of ‘skip’ bone
lesions) [24]. Additional appropriate imaging studies and biop-
sies can be taken from suspicious sites, as the exact staging of the
disease has an impact on treatment and outcome.
No specific laboratory tests for the diagnosis of bone sarcoma are
routinely available. Baseline serum analysis in ES and OS should in-
clude alkaline phosphatase (AP) and lactate dehydrogenase (LDH),
given their proven prognostic value [25–27]. Prognostic features
also include clinical presentation: a pathological fracture may lead
to the dissemination of tumour cells into surrounding tissues and
increase the risk of local recurrence. In cases of fracture, internal fix-
ation is contraindicated as it disseminates the tumour further into
both bone and soft tissues and increases the risk of local recurrence.
External splintage is recommended.
ChT can result in renal, cardiac and auditory dysfunction.
Before starting the treatment, baseline renal function testing, as-
sessment of cardiac function [left ventricular ejection fraction
(LVEF)] and audiogram (in the case of platinum derivatives)
should be carried out. Sperm storage is recommended for male
patients of reproductive age. For female patients, a fertility phys-
ician is routinely consulted about potential ovarian tissue sam-
pling and cryopreservation in some but not all countries,
reflecting a variability of healthcare policies across nations.
Treatment (locoregional and advanced
disease)
Given the rarity of the disease and the complexity of manage-
ment, the accepted standard for bone sarcomas is treatment at
reference centres and/or within reference networks able to
provide access to the full spectrum of care and age-specific ex-
pertise [III, A]. In these centres/networks, therapy is usually
given within either the framework of prospective, often collab-
orative, clinical studies or established treatment protocols.
In the case of high-grade OS, ES or pleomorphic sarcoma, fol-
lowing biopsy proven-diagnosis, primary ChT is generally rec-
ommended by expert centres.
Osteosarcoma
OS usually arises in the metaphysis of a long bone, most com-
monly around the knee in children and adolescents. Involvement
of the axial skeleton and craniofacial bones is primarily observed
in older patients. High-grade OS frequently metastasises, the
lung being the most frequent metastatic site by far, followed by
distant bones.
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Conventional OS is always high-grade. Parosteal OSs are low-
grade malignancies, although they may increase in size and in-
vade the medulla of bone, and transform to high-grade sarcoma,
whereas periosteal OS is an intermediate-grade chondroblastic
OS, sometimes difficult to distinguish from high-grade surface
OS. Adverse prognostic or predictive factors for conventional OS
include detectable primary metastases, axial or proximal extrem-
ity tumour site, large tumour size, elevated serum AP or LDH
and older age [III, B] [25, 26]. As mentioned above, staging
should include local imaging studies, specifically plain radio-
graphs and MRI of the whole affected extremity [III, A].
Curative treatment of high-grade OS consists of ChT and sur-
gery [II, A]. Compared with surgery alone, multimodal ChT
treatment of high-grade localised OS increases disease-free sur-
vival probability from 10%–20% to > 60%. In general, ChT is
administered before and after surgery, although a formal proof
that giving ChT preoperatively improves survival is lacking. The
extent of histological response to preoperative ChT predicts sur-
vival [25–27].
Low-grade parosteal OSs are malignancies with a lower meta-
static potential and should be treated by surgery alone [IV, B].
Although ChT has been used for periosteal OSs, no benefit for
ChT was shown in retrospective analyses [28–30], and its use is
not routinely recommended in this setting [IV, D].
Surgery should be carried out by a surgical team familiar with
the wide range of surgical reconstructive options. Paediatric and
adolescent patients need to be treated by surgeons with great ex-
perience in the field of paediatric bone tumours, including age-
specific reconstruction challenges, such as the reconstruction of
growing bones. The goal of surgery is to safely remove the tumour
and yet preserve as much function as possible, striving to obtain
microscopically clear surgical margins [27]. Most patients should
be considered candidates for limb salvage. Either intralesional or
marginal margins increase the local relapse rate, which is associated
with reduced overall survival. Thus, clear margins are the first goal
of surgery [III, B]. Areas where there is suspicion of close margins
should be marked on the surgical specimen sent to pathology.
Pathological fracture does not necessarily necessitate an ampu-
tation. In chemosensitive tumours, primary neoadjuvant ChT
can be used with the expectation that it will allow the fracture
haematoma to contract and allow subsequent resection of the tu-
mour and the involved soft tissues [31].
Doxorubicin, cisplatin, high-dose methotrexate (HD-MTX)
and ifosfamide have antitumour activity in OS [I, A] [32–
35]. The MAP (doxorubicin/cisplatin/HD-MTX) regimen is
most frequently used as the basis of treatment in children
and young adult patients [30]; however, HD-MTX can be
difficult to manage in adults. In patients aged > 40, regi-
mens combining doxorubicin, cisplatin and ifosfamide with-
out HD-MTX can also be used in these patients [III, B]
[33–36]. These drugs should be administered with adequate
supportive care by experienced paediatric oncologists or
medical oncologists at reference institutions with appropriate
infrastructure and a multidisciplinary treatment approach.
Most current protocols include a period of preoperative
ChT, to facilitate local surgical treatment and to allow the
assessment of tumour response [32–41]. The EURAMOS 1
prospective trial aimed to establish whether PEGylated
interferon alpha-2b (PEG-IFNa-2b), in addition to standard
MAP ChT given postoperatively, could improve outcome in
patients with good histological response to preoperative
MAP. The results showed that many patients failed to start
and complete interferon treatment, and there was no signifi-
cant overall survival advantage [I, C] [34, 35]. The study
also evaluated if altering postoperative ChT in poor respond-
ers to preoperative systemic therapy might have any impact
on outcome, and, again, no survival benefit was proven. In
case of poor pathological response to the preoperative MAP
regimen, the postoperative addition of ifosfamide and etopo-
side to MAP failed to improve the survival and increased the
risk of secondary malignancy compared with those patients
treated with the MAP regimen only [I, C] [36]. Whenever
possible, patients with OS should receive ChT in the context
of prospective studies.
Innate immune-modulation has been attempted in OS with
other agents, in particular muramyl tripeptide. As described
above, the use of interferon failed to show a survival advantage in
patients with a good histological response to an MAP-
preoperative regimen. Muramyl tripeptide added to postopera-
tive ChT was associated with a significant advantage in overall
survival and a non-significant trend in event-free survival in one
large randomised trial [II, C] [41]. Muramyl tripeptide has been
approved in Europe for patients< 30 years of age with complete-
ly resected localised OS, but it is not reimbursed in all European
countries. There is no consensus in the sarcoma community on
the use of this drug, due to weaknesses in the data from the only
trial currently available [41, 42]. Further studies are needed to
identify any subgroup of patients who could benefit from im-
mune modifying agents.
Dynamic MRI is reliable for evaluation of changes in tumour
vascularity and to give additional information on tumour re-
sponse to primary ChT [43, 44]. The value of diffusion MRI is
currently under evaluation [44].
The multimodal treatment principles detailed above were gen-
erated in children, adolescents and young adults with high-grade
central OS, but also relate to adults [III, B]. Adult patients may re-
quire tailored regimens, especially as far as HD-MTX is con-
cerned, in particular for those aged> 40 years. Some studies have
put a threshold of 25 years of age to remove HD-MTX from the
induction regimen [45], while others included HD-MTX for
older patients [46]. Doxorubicin plus cisplatin and/or ifosfamide
are commonly used with age-adapted doses. Recently, the add-
ition of zoledronic acid was tested in a randomised setting and
failed to demonstrate an improvement in relapse-free or overall
survival or histological response. Its use is, therefore, not recom-
mended outside clinical trials [I, D].
In general, there is no indication for RT, but there are anatom-
ical locations in which the possibility of complete surgical resec-
tion is limited. In these cases, after a multidisciplinary discussion,
RT may be an option to try to extend the progression-free inter-
val. This must be discussed in a multidisciplinary team before-
hand and with the patient, and it should be made clear at the time
of surgery that the goal is not an R0 resection (excision whose
margins are clear of tumour cells) [V, C]. New RT techniques
(e.g. proton and carbon ion beam RT) should be considered, par-
ticularly for unresectable primary tumours [47].
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Primary metastatic OS patients are treated with a curative in-
tent following the same principles of non-metastatic OSs [48]. In
fact, there are subsets of patients who can have a very similar
prognosis to that of localised disease, provided surgical removal
of all known metastatic deposits is achievable [III, B] [49].
Approximately 25% of all patients with primary metastatic OS
and > 40% of those who achieve a complete surgical remission
may become long-term survivors.
High-grade craniofacial OS should be treated the same way as
high-grade OS of other locations, although prospective evidence
is lacking due to the absence of selective clinical studies in this pa-
tient population [IV, B]. PET-CT scanning may be advantageous
for response assessment [50]. RT, preferably within clinical stud-
ies, can be proposed when complete surgery is not feasible [IV,
B]. The value of proton/carbon ion beam RT in this setting is cur-
rently under study. Adjuvant RT follows the same recommenda-
tions as that for other sites (see above).
The management of recurrent OS needs to take into account
the timing of recurrences/metastases, the number of metastases
and the metastatic sites. CT scan can over- and under-estimate
the number of pulmonary metastases, but the recent results have
improved with spiral CT. The treatment of recurrent OS is pri-
marily surgical in the case of isolated lung metastases. Complete
removal of all metastases must be attempted [III, B], as the dis-
ease is otherwise almost universally fatal; more than a third of
patients with a complete second surgical remission survive for
> 5 years [51]. Even patients with subsequent recurrences may
be cured as long as recurrences are resectable, and repeated thora-
cotomies are often warranted [51]. For lung metastases, stereo-
tactic RT, radiofrequency ablation or cryotherapy might be used
as alternative options in patients unfit for surgery [IV, B]. Some
groups also consider radiofrequency ablation [52, 53] and stereo-
tactic RT [54] to be potential alternative local treatment options
for primary lung or bone metastases [52–54].
The role of second-line chemotherapy for recurrent OS is
much less well defined. Treatment choice may take into account
the prior disease-free interval, and often includes ifosfamide or
cyclophosphamide, possibly in association with etoposide and/or
carboplatin [III, B]; other active drugs and combinations include
gemcitabine and docetaxel [IV, C], sorafenib [III, B] or regorafe-
nib [II, B], as well as samarium (153Sm); the evidence for these
drugs is limited and there are reimbursement constraints [55–60].
In the two largest reported series, the use of second-line ChT corre-
lated with limited prolongation of survival in patients with inoper-
able metastatic recurrences, while a positive correlation in operable
disease was observed in only one of the two [49, 50]. However,
radiological responses and clinical benefit are commonly witnessed
so that its use should be considered [IV, B].
RT may have a role in palliation. In general, despite second-
line treatment, the prognosis of recurrent disease has remained
poor, with a long-term post-relapse survival rate of < 20% [48,
49, 51].
Ewing sarcoma
ES is a small, blue, round cell tumour, periodic acid-Schiff (PAS)
positive and CD99 (MIC2)-positive. All ESs are high-grade
tumours. They can arise both from bone, soft tissues or visceral
sites, displaying the same behaviour in principle.
The definitive diagnosis is made by biopsy, providing sufficient
material for conventional histology, immunohistochemistry,
molecular pathology and biobanking. Molecular biology studies
have shown that almost all of these tumours share a common
TET-ETS gene rearrangement involving the EWSR1 gene on
chromosome 22 [61–64]. In most cases, this involves a reciprocal
translocation t(11; 22)(q24; q12) [47], but t(21; 22)(q22; q12),
and others may also occur [t(7; 22), t(17; 22) and t(2; 22)] [61–
64]. In recent years, new small round cell sarcoma entities have
been recognised, with novel translocations, among which BCL6
corepressor (BCOR)-rearranged sarcoma preferentially affects
the bone. Other examples of recurrent molecular alterations
found in these malignancies include EWS RNA binding protein
1—nuclear factor of activated T cells 2 (EWSR1-NFATC2), FUS
RNA binding protein—nuclear factor of activated T cells 2 (FUS-
NFATC2), capicua transcriptional repressor—forkhead box O4
(CIC-FOXO4) or capicua transcriptional repressor—double
homeobox 4 (CIC-DUX4) translocations (see Table 1) [65–67].
Current investigations have shown that tumour biology and
prognosis of these tumours, which are probably different noso-
logical entities rather than molecular variants, actually differ
from classical ES, making molecular testing mandatory.
Currently, patients presenting with these variants are treated
with Ewing-like regimens, although their best treatment and even
their natural history are poorly known [65–67]. Inclusion in pro-
spective registries is worthwhile [a European Reference Networks
on adult rare solid cancers (EURACAN) sarcoma project is
planned].
Although most ES tumours can be recognised with classical
haematoxylin and eosin (H&E) stain, immunohistochemistry
molecular confirmation is mandatory for the identification of the
classical and distinct molecular subtypes as described above [III,
A] [18, 62–67]. The laboratory should be enrolled in an external
quality assurance programme. When frozen tissue is available,
techniques that identify both fusion partners (i.e. RT-PCR or
anchored, multiplex PCR-based, targeted NGS) are the techni-
ques of choice. The latter can also be applied to non-decalcified
or EDTA-decalcified, formalin-fixed paraffin-embedded (FFPE)
tissue. FISH is a good choice when only FFPE tissue [or touch
preparations (imprints)] are available. There are several commer-
cial sources for EWSR1 break-apart probes. Assays using EWSR1
break-apart probes do not detect EWS-FLI1 fusions, but only
EWSR1 rearrangements, which should not be a problem when
interpreted in the appropriate clinical and pathological context.
NGS should be considered when no typical translocation has
been detected by conventional methods.
Bone marrow biopsies and aspirates (from sites distant to the
primary or known metastatic lesions) may be considered in the
staging, but several experts underline that there is a very low inci-
dence of bone marrow metastases in localised disease if the PET
scan is negative [68]. The added prognostic value of molecular
positivity over light microscopic evaluation has not yet been pro-
ven [IV, C].
Between 20% and 25% of patients are diagnosed with metastat-
ic disease [lung (10%); bone/bone marrow (10%); combinations
or others (5%)] [69, 70]. Staging must be oriented to detect lung,
bone and bone marrow metastases and should include biopsy in
case of doubtful lesions. Multiple bone metastases confer a
poorer outcome than lung/pleural metastases (< 20% compared
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with 20%–40% 5-year survival). Other known adverse prognos-
tic factors are large tumour size or volume, elevated serum LDH
levels, non-extremity localisation and age > 15 years. A poor
histological response to preoperative ChT and incomplete or no
surgery for local therapy are further adverse prognostic factors
[71–75]. The molecular structure of the EWSR1 fusion tran-
scripts has not been shown to be of prognostic value with current
treatment protocols. Genomic analysis with the assessment of copy
number variation has been shown to be of prognostic value [75,
76]. In addition, STAG2, TP53 and CDKN2A mutations confer
poorer outcomes. With surgery or RT alone, i.e. without systemic
treatments, 5-year survival was< 10%. With the currently recom-
mended multimodal approaches including ChT, 5-year survival is
 60%–75% in localised and 20%–40% in metastatic disease, re-
spectively, depending on metastatic sites and burden (Figure 2).
Current trials employ 3–6 cycles of initial combination ChT
after biopsy, followed by local therapy, and another 6–10 cycles of
ChT, usually applied at 2- to 3-week intervals. Treatment dur-
ation is thus 10–12 months. Agents considered to be most active
include doxorubicin, cyclophosphamide, ifosfamide, vincristine,
dactinomycin and etoposide [77–81]. Almost all active protocols
are based on five- to six-drug combinations of these substances
[I, A]. Dose-dense regimens (with interval compression) were
associated with a positive outcome in paediatric and adolescent
(<18 years) patients in a prospective North American study
[II, B] [82].
The use of high-dose ChT with escalated alkylating agent dose
and blood stem cell rescue has attracted much attention in ES
since the 1970s. Only recently have the results of randomised
studies with busulfan and melphalan (BuMel) indicated that this
approach results in a survival advantage for tightly defined and
highly selected patients with poor response to induction ChT
and/or tumour volume> 200 mL [I, B] [83, 84]. No such advan-
tage was evident for patients presenting with pulmonary metasta-
ses [II, D] (Figure 2).
ES is a radiosensitive tumour at lower doses than OS. The goal
of local therapy for the primary tumour is to ensure that the en-
tire volume of tissue involved at diagnosis is treated. Complete
surgical excision, where feasible, is regarded as the best modality
of local control, given the higher risk of local recurrence when RT
is used as the sole treatment of the primary tumour. Surgery must
involve excision of all tissues originally involved with tumour
(not just the tissue that is left after ChT shrinkage) or be supple-
mented by RT. RT alone (in the range of 45–60 Gy, depending on
location) should be applied if complete surgical excision is im-
possible. Postoperative RT should be given in cases of inadequate
surgical margins and discussed when histological response in the
surgical specimen was poor (i.e. > 10% viable tumour cells) [IV,
B] [78]. The dose of postoperative RT is also 45–60 Gy, depend-
ing on margins, response and location. Intralesional surgery must
be avoided, as there is no benefit when compared with RT alone
[78]. Change in the size of the soft tissue mass is easily evaluated
on MRI and is a good predictor of tumour response [43, 44].
Dynamic MRI is not as reliable as in OS [44], as remaining small
tumour foci may not be detected. Sequential FDG-PET evalu-
ation might be of additional value [85].
The treatment of adult patients follows the same principles as
for children. However, tolerability of therapies in older patients
needs to be taken into account when transferring treatment
Table 1. Personalised medicine synopsis table
Biomarker Method Use LoE GoR
Genomic characterisation PCR, FISH, NGS Small round cell sarcoma III A
FISH, ﬂuorescent in situ hybridisation; GoR, grade of recommendation; LoE, level of evidence; NGS, next-generation sequencing; PCR, polymerase chain
reaction.
Suspected primary 
bone cancer on X-ray
Imaging of the primary bone tumour:
MRI for limb sarcoma
CT scan for trunk/head/neck
Grading
Biopsy and 
histological and 
molecular assessment
Staging: CT scan, PET scan, 
BM biopsy (Ewing)
Clinical and biological assessment 
(depends on histotype)
Confi rmed histological 
diagnosis
Optional: storage of 
frozen tumour tissue
Figure 1. General diagnostic strategy for bone sarcomas.
BM, bone marrow; CT, computed tomography; MRI, magnetic reson-
ance imaging; PET, positron emission tomography.
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protocols conceived for children and patients of age  40–
50 years. Treatment of patients with extraskeletal ES follows the
same principles as for bone ES, thus incorporating ChT in all
cases as well as postoperative RT in most cases, with the possible
exception of superficial lesions. For extraskeletal ES, postopera-
tive RT is generally used, with the possible exception of good
prognosis, superficial ES.
Patients with metastases at diagnosis are treated with the same
treatment approach as patients with localised disease but have a
worse prognosis. In patients with lung metastases, whole-lung ir-
radiation may confer a survival advantage [III, C] [86]. The role of
surgical resection of residual metastases is less well defined.
For patients presenting with extra-pulmonary metastases,
survival is even worse (< 20%) [87]. ChT is similar to that for
localised disease but responses are less durable. Treatment of
the primary tumour is often appropriate, especially in the pres-
ence of responding metastatic disease. There is no formal evi-
dence for high-dose ChT in this situation; therefore, practices
diverge among centres. No randomised studies have been
reported for this approach.
Recurrent ES, whether local or with distant metastases, is almost
always fatal, even though further responses to ChT are frequent
and valuable. The only prognostic factor identified in relapsed
patients seems to be time to relapse: patients relapsing later
than 2 years from initial diagnosis have a better outcome [88].
Doxorubicin therapy is usually no longer feasible due to previously
achieved cumulative doses. ChT regimens in relapse situations are
not standardised and include alkylating agents (cyclophosphamide
and high-dose ifosfamide) in combination with topoisomerase
inhibitors (etoposide and topotecan), irinotecan with temozolo-
mide [III, B] or gemcitabine and docetaxel, or high-dose ifosfamide
or carboplatin with etoposide [89, 90]. The relative advantages of
these different regimens are currently being tested in an inter-
national randomised study [European Organisation for Research
and Treatment of Cancer (EORTC) trial 1403 European Clinical
Trials Database (EudraCT) 2014-000259-99/ISRCTN36453794].
High-grade spindle/pleomorphic sarcomas of bone
Pleomorphic sarcomas of bone comprise a diagnostically heteroge-
neous group of malignant tumours including undifferentiated
pleomorphic sarcoma [8]. They arise in a similar age group to CS,
but the skeletal distribution is more like OS. They typically present
with pain and have a high incidence of fractures at presentation.
They represent between 2% and 5% of primary bone malignancies.
Males are more frequently affected than females. An association
with pre-existing disease (Paget disease or bone infarct) or history
of previous irradiation has been reported. It is not unusual for a
spindle cell sarcoma to be found to be either a dedifferentiated CS
or OS after examining further different sections of the resection.
Therefore, the diagnosis should be established in a multidisciplin-
ary setting and IDH mutation analysis should be considered when
the radiological images suggest a CS.
Pleomorphic sarcomas typically present in older patients with a
lytic lesion in bone. A metastatic lesion is often a differential diagno-
sis. Full staging and biopsy are required to reach a diagnosis.
Pathological fractures are common and, as mentioned in the intro-
duction, should not undergo internal fixation [91, 92]. Treatment
strategies mimic those of OS, with ChT and complete en bloc
resection including any soft tissue component. Their sensitivity to
ChT is poorly known, and studies on specific histologies as currently
defined [especially after reappraisal of histologies previously known
as malignant fibrous histiocytoma (MFH)], are highly required. RT
may be considered in inoperable lesions. A global effort to collect
these cases would be helpful to establish diagnostic and prognostic
criteria as well as recommended treatments, for the whole group as
well as for the different histologies.
Chondrosarcoma
Most CSs arise as primary malignant tumours. The majority of
CSs are low-grade, locally aggressive, non-metastasising tumours
(atypical cartilaginous tumour/CS grade I), rather than high
grade (grades II–III) [18, 93]. Grade I CSs can be labelled atypical
cartilaginous tumours, as currently defined by the WHO 2013
classification, since they usually do not metastasise [18]. Grade I
CSs may be treated with RT when located at critical sites such as
the skull base. Most CSs arise centrally in the metaphyseal region
of long bones, but they can also develop in flat bones such as pel-
vis, rib and scapula. High-grade CS frequently arises in the axial
skeleton and long bones. CS can arise in pre-existing benign
lesions such as enchondroma and osteochondroma [6]. In these
circumstances, they are referred to as secondary central CSs and
secondary peripheral CSs, respectively. The majority of CSs are of
the conventional subtype, but rarer subtypes include mesenchy-
mal and clear cell CS [33, 94]. In rare circumstances, convention-
al CSs can ‘dedifferentiate’ into a very high-grade tumour with a
dismal prognosis: the so-called dedifferentiated CS [33, 94].
Most CSs are solitary, but they can occur as multiple lesions
in syndromic patients with multiple osteochondromas and
enchondromatosis [6].
Pain at the site of a cartilaginous lesion may be an indicator of
malignancy. In the case of CS, a contrast-enhanced MRI can reveal
high-grade areas. This provides a useful guide to the site of biopsy
[95]. For large axial and pelvic CS, heterogeneity is common, and
most lesions contain high-grade elements. The differentiation be-
tween benign enchondroma or osteochondroma and atypical car-
tilaginous tumour/CS grade I can be difficult, but can be aided by
the use of dynamic contrast-enhanced MRI [96]. In the phalanges
of the hands and feet, malignancy is extremely rare, but in the other
long bones central cartilaginous lesions should be considered atyp-
ical cartilaginous tumour unless proven otherwise [94].
Inoperable, locally advanced and metastatic high-grade CSs
have a poor prognosis [97]. Prognosis depends on histological
grade. However, histological classification is subject to variability
in interpretation, with grade II and III CSs often grouped to-
gether, even though there is a wide spectrum of outcome and het-
erogeneity of grade elements within tumours [74]. Also, grade I
tumours (atypical cartilaginous tumours) are not necessarily cur-
able in all cases, mainly due to problematic local recurrence or
progression to high grade. Conversely, dedifferentiated CSs in
particular are aggressive and frequently metastasise [33, 94].
Assessing the grade of CSs is difficult and discrepant diagnoses
are common even among experts [93]. Atypical cartilaginous
tumours are unlikely to metastasise, but may recur locally.
Atypical cartilaginous tumours in the long bones of the limbs can
be managed by curettage with or without local adjuvant (e.g. phe-
nol, cement and cryotherapy), with a high chance of success.
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Low-grade peripheral CSs (arising from osteochondromas)
should be surgically excised, aiming to excise the tumour with a
covering of normal tissue over it. Higher-grade CSs (grade II and
III) and all CSs of the pelvis or axial skeleton should be surgically
excised with wide margins [IV, B].
Evidence suggests that mesenchymal CS is more sensitive to
ChT and therefore usually considered for adjuvant or neoadju-
vant therapy [IV, C] [98, 99]. Most authors suggest a Ewing-type
ChT regimen.
Dedifferentiated CS is often treated as a high-grade bone sarcoma,
with systemic and local therapies that need to be adapted to patient’s
age [V, C] [100, 101]. There is a very high risk of local recurrence fol-
lowing excision of dedifferentiated CS, particularly in the presence
of a pathological fracture. If wide margins cannot be reliably
achieved with limb salvage, amputation should be considered.
The role of RT in CS is limited, but may be appropriate in highly
selected cases or for palliation. Excellent outcomes have been
reported for skull base CSs with high-dose RT, including proton or
carbon ion beam RT, achieving 80%–90% local control rates [102].
With regard to ChT, drugs active in sarcomas such as doxo-
rubicin and ifosfamide may prove active in CS, especially in high-
grade lesions [97]. The activity of gemcitabine in combination
with docetaxel has been reported [103].
Giant cell tumour of bone
GCT of bone is a benign, locally aggressive and rarely metastatic
tumour of the skeleton [9, 104]. GCT is classified in the inter-
mediate category, as GCT can be aggressive and recurs locally in
up to 50% of cases [9, 104]. Soft tissue extension is significantly
associated with the risk of local recurrence. Up to 5% of GCTs
metastasise to the lungs, and transformation to a high-grade ma-
lignancy though debated, may occur in 1%–3% of patients. GCTs
of bone contain mutations in the H3F3A gene (predominantly at
the G34 position) which can be detected using mutation analysis
or immunohistochemistry using mutation-specific antibodies
[104, 105].
Treatment options include en bloc excision [IV, A] and intrale-
sional curettage with or without adjuvant in carefully selected
cases. These have been assessed in a few prospective studies [106,
107]. Denosumab, a human monoclonal antibody to receptor ac-
tivator of nuclear factor kappa B ligand (RANKL), known to be
overexpressed in GCT, is standard treatment in unresectable or
metastatic GCT [III, A] [107]. Its use in the neoadjuvant setting is
debated and should be carried out exclusively in expert centres,
and ideally within a clinical trial. There is increasing evidence
that, if being used preoperatively and before curettage, surgery is
best carried out after a few months of treatment, as otherwise ex-
tensive ossification may take place, making it difficult to define
the extent of the lesion [V, C] [108]. It can also be used in unre-
sectable disease and rare metastatic disease. In this setting, treat-
ment interruption is usually followed by progression, so that
treatment needs to be maintained [109]. Potential maxillar and
skeletal side effects need to be monitored (osteonecrosis of the
jaw, atypical fractures). The optimal schedule and duration of
treatment with denosumab in surgically unsalvageable GCTs is
still to be settled, and the possible long-term side effects are still
largely unknown.
RT can provide a satisfactory local control in GCT (5-year con-
trol rate of 80%) [110]. However, the use of radiotherapy can be
associated with a risk of GCT transformation into a high-grade
sarcoma and can make surgical resection challenging if required.
Therefore, the use of RT in GCTs should always be discussed in a
multidisciplinary setting and be limited to cases in which surgery
leads to unacceptable morbidity and denosumab is ineffective or
contraindicated [IV, D].
Chordoma
Chordoma is a rare bone tumour (incidence: 0.1 per 100 000 per
year) arising from the persistent notochordal elements in the
spine (sacrum 50% and bones from the mobile spine 20%) and in
the skull base (30%). Extraskeletal cases are extremely rare.
Median age is 60 years, but skull base presentations can also af-
fect a younger population, including children and adolescents.
Conventional chordoma is a low-grade, locally-invasive malig-
nancy. Immunohistochemistry nuclear positivity for Brachyury
is the diagnostic hallmark and its assessment is strongly recom-
mended [111]. Dedifferentiated chordomas account for less than
5% of all cases and behave more aggressively than the conven-
tional counterpart. T expression can be lost in dedifferentiated
chordoma. Approximately 30% of patients with chordoma will
develop metastases, usually late in the natural history of the dis-
ease, and mostly after local recurrence.
Because of the extreme rarity and the challenging sites of ori-
gin, chordoma management should be carried out at referral
centres and/or referral networks, with a multidisciplinary team
including expert pathologists, radiologists, dedicated surgeons,
radiation oncologists with access to hadron facilities, medical
oncologists and a palliative care team.
Local staging should be carried out by MRI. Chordoma should
be differentiated from benign notochordal cell tumours, benign
lesions with peculiar radiological features believed to be chor-
doma precursors [112]. If radiological appearance is typical for
benign notochordal cell tumours, biopsy is not recommended
unless the lesion changes over time. For chordoma, preoperative
core-needle biopsy is recommended and the biopsy track needs
to be included in the surgical resection. For skull base chordoma,
preoperative biopsy is not recommended if the tumour cannot be
reached easily or safely, or if there is a high risk of tumour cell
seeding [V, C] [113].
En bloc R0 resection is the recommended treatment, when feas-
ible and sequelae are accepted by the patient [IV, B]. The
expected 5-year recurrence-free survival is > 50%. For sacral
chordoma, surgery should definitely be offered as a first choice in
case of lesions arising from S4 (sacral spinal nerve 4) and below.
It should always be discussed in the context of other alternatives
for tumours originating above S3 (sacral spinal nerve 3), given
the neurological sequelae associated to surgical resection. For
skull base and upper cervical tract chordoma, R0 resection can
rarely be done. R1 (microscopic positive margin) should be the
goal of surgery in these cases [V, B]. Adjuvant RT should always
be considered for skull base and cervical spine chordomas, and
for sacral and mobile spine chordoma if R1-resected chordoma is
observed in the final pathological examination.
If en bloc R0 resection is not feasible, the patient is inoperable
or surgical sequelae are not accepted by the patient, definitive RT
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alone (without debulking) is an alternative [V, C]. Particle ther-
apy (high-dose protons or carbon ions) provide a better local
control, survival and allow lower doses to be given to normal tis-
sues and should, therefore, be considered the treatment of choice
[IV, B] [114, 115]. Very conformal photon irradiation should
only be proposed when similar dose uniformity within the target
volume and dose to organs at risk can be achieved [V, B]. Due to
the relative radiation resistance of chordomas, a high dose [up to
at least 74 GyE in conventional fractionation (1.8–2 GyE) for
photon and proton therapy] is required.
The use of neoadjuvant RT should be discussed with the single
patient and prospective studies encouraged.
Local relapse has extremely poor survival rates and local
control is rarely achievable. In the case of local relapse, possible
salvage treatment can include surgery and/or RT and/or radio-
frequency ablations and/or systemic treatment, balancing mor-
bidity, quality of life and expected disease control [116].
For oligometastatic disease, surgery, radiofrequency ablations
or stereotactic radiation can be considered in selected cases. ChT
is inactive and is generally not recommended [V, D]. An excep-
tion can be high-grade dedifferentiated chordoma (anecdotal
responses to ChT have been reported). There is uncontrolled evi-
dence that imatinib and sorafenib can be beneficial in advanced
chordoma in terms of progression-free survival and mainly non-
dimensional tumour responses [117–119]. There are data on the
activity of epidermal growth factor receptor and mammalian tar-
get of rapamycin (mTOR) inhibitors. Prospective studies are
ongoing.
Follow-up, long-term implications and
survivorship
Follow-up is designed to detect either local recurrence or meta-
static disease at a time when early treatment is still possible and
might be effective. Follow-up of high-grade tumours should in-
clude both a physical examination of the tumour site and assess-
ment of the function and possible complications of any
reconstruction. Local imaging and chest X-ray/CT could be a
proposed strategy. Strict rules cannot be provided in the absence
of any formal prospective studies, and in the context of differing
opinions in this panel of experts. A recommended follow-up pol-
icy may foresee intervals between checks after the completion of
ChT, approximately every 3 months for the first 2 years; every
6 months for years 3–5; every 6–12 months for years 5–10, and
thereafter every 0.5–2 years according to local practice and other
factors. Chest CT, if used instead of chest X-rays, should be car-
ried out with low-dose, radiation-sparing techniques, particular-
ly in younger patients who will have a higher lifetime risk to
experience second, radiation induced malignancies.
In the case of low-grade bone sarcoma, the frequency of
follow-up visits may be lower (e.g. 6 months for 2 years and then
annually). Late metastases as well as local recurrences and func-
tional deficits may occur > 10 years after diagnosis and there is
no universally accepted stopping point for tumour surveillance.
In ES, where osseous metastases are likely, isotope bone scan-
ning can be used in addition to X-ray imaging but should be
weighed against the additional radiation exposure, particularly in
younger patients. More modern techniques (e.g. PET or whole-
body MRI) are increasingly being adopted into routine practice
but require further evaluation in clinical trials. This is a general
priority for all cancers.
There is a lack of consensus among experts about optimal
follow-up policies, taking into consideration the specific risk and
performance of systematic imaging follow-up regarding the me-
dian and long-term risk of second cancers. Some panellists pro-
pose 6-monthly follow-up, whereas others suggest 3-month
intervals. Some propose interruption of systematic follow-up at
5 years, while others maintain it beyond 10 years. National guide-
lines may also be different across countries [120]. The lack of con-
sensus and the very limited number of prospective trials point to
the need to generate prospective clinical trials on this topic in the
future.
It is important to evaluate the long-term toxic effects of ChT,
surgery and RT for cured patients, given the incidence of late
complications. Monitoring for late effects should be continued
for > 10 years after treatment, depending on the ChT protocol
and radiation used and in conjunction with late effects services
when available. Long-term cardiac evaluation is of major import-
ance since it has been shown that deterioration of cardiac
function can still occur decades after anthracycline treatment
[120–122].
Secondary cancers may arise in survivors of bone sarcomas, ei-
ther related to, or independent of, irradiation. Secondary leukae-
mia, particularly acute myeloid leukaemia, may rarely be
observed following ChT, as early as 2–5 years after treatment.
Developments in genetic understanding of bone sarcoma point
to the importance of obtaining a detailed family history and of
genetic evaluation in high-risk families. Patients with cancer pre-
disposition syndromes (e.g. Li–Fraumeni or Rothmund–
Thomson syndromes) require special care and follow-up.
Methodology
These Clinical Practice Guidelines have been produced by ESMO in
partnership with EURACAN, the European Reference Network for
rare adult solid cancers. These Clinical Practice Guidelines were
developed in accordance with the ESMO standard operating proce-
dures for Clinical Practice Guidelines development (http://www.
esmo.org/Guidelines/ESMO-Guidelines-Methodology). They are
conceived to provide the standard approach to diagnosis, treatment
and survivorship on sarcomas, GISTs and bone sarcomas.
Recommended interventions are intended to correspond to the
‘standard’ approaches, according to current consensus among the
European multidisciplinary sarcoma community of experts. These
are represented by the members of the ESMO Sarcoma Faculty and
experts appointed by PaedCan and all institutions belonging to the
Sarcoma domain of EURACAN.
Experimental interventions considered to be beneficial are
labelled as ‘investigational’. Other non-standard approaches may
be proposed to the single patient as ‘options’ for a shared patient
physician decision in conditions of uncertainty, as long as some
supporting evidence (though not conclusive) is available.
Algorithms accompany the text, covering the main typical presenta-
tions of disease, and are meant to guide the user throughout the
text. The relevant literature has been selected by the expert authors.
A summary of recommendations is shown in Table 2. Levels of
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Table 2. Summary of recommendations
Diagnosis and pathology/molecular biology
• Management of bone sarcomas should be carried out in a reference centre for bone sarcomas, with a primary biopsy under the supervision of a surgical
team or dedicated interventional radiologist
• Pathological diagnosis should be made according to the 2013 WHO classiﬁcation
• Medical history should focus on characteristic symptoms such as duration, intensity and timing of pain, persistent non-mechanical bone pain, swelling and
functional impairment
• Diagnosis can be strongly oriented by patient age
Staging and risk assessment
• General staging should be carried out to assess the extent of distant disease, including bone scintigraphy, chest radiographs and CT, whole-body MRI and
PET-CT or PET-MRI
Treatment (locoregional and advanced disease)
Osteosarcoma
• Adverse prognostic or predictive factors include detectable primary metastases, axial or proximal extremity tumour site, large tumour size, elevated serum
AP or LDH and older age [III, B]
• Staging should include local imaging studies, speciﬁcally plain radiographs and MRI of the whole affected extremity [III, A]
• Curative treatment of high-grade OS consists of ChT and surgery [II, A]; multimodal ChT treatment is preferred
• Low-grade parosteal OSs are malignancies with a lower metastatic potential and should be treated by surgery alone [IV, B]
• Doxorubicin, cisplatin, HD-MTX and ifosfamide have antitumour activity in OS [I, A]. In patients aged > 40, preferred regimens often combine doxorubicin,
cisplatin and ifosfamide without HD-MTX [III, B]
• In limited cases, RT including new techniques (e.g. proton and carbon ion beam RT) should be considered, particularly for unresectable primary tumours
• Primary metastatic OS patients are treated with a curative intent following the same principles of non-metastatic OSs
• High-grade craniofacial OS should be treated the same way as high-grade OS of other locations, although prospective evidence is lacking [IV, B]. RT,
preferably within clinical studies, can be proposed when complete surgery is not feasible [IV, B]
• The treatment of recurrent OS is primarily surgical in the case of isolated lung metastases, although stereotactic RT, radiofrequency ablation or cryotherapy
might be used as alternative options in patients unﬁt for surgery [IV, B]
• Radiofrequency ablation and stereotactic RT are potential alternative local treatment options for primary lung or bone metastases
• Second-line ChT for recurrent OS includes ifosfamide or cyclophosphamide, possibly in association with etoposide and/or carboplatin [III, B], and other active
drugs including gemcitabine and docetaxel [IV, C], sorafenib [III, B] or regorafenib [II, B], as well as 153Sm
Ewing sarcoma
• ES is a rare tumour and is usually treated within speciﬁc ChT regimens
• Treatment of patients with extraskeletal ES follows the same principles as for bone ES and incorporates ChT in all cases, as well as postoperative RT in most
cases
• Complete surgical excision, where feasible, rather than RT alone, is regarded as the best modality of local tumour control
• RT alone should be applied if complete surgical excision is impossible
• Postoperative RT should be given in cases of inadequate surgical margins and discussed when histological response in the surgical specimen was poor
[IV, B]
• Preferred ChT options include doxorubicin, cyclophosphamide, ifosfamide, vincristine, dactinomycin and etoposide, with most active protocols based on
ﬁve- to six-drug combinations of these substances [I, A]
• Current trials employ 3–6 cycles of initial combination ChT after biopsy, followed by local therapy, and another 6–10 cycles of ChT, usually applied at 2- to
3-week intervals
• Dose-dense regimens (with interval compression) were associated with a positive outcome in paediatric and adolescent (<18 years) patients [II, B]
• Recent studies recommend the use of BuMel for highly selected patients with poor response to induction ChT and/or tumour volume > 200mL [I, B]
• For patients with metastases at diagnosis, ChT is similar to that for localised disease, but responses are less durable and patients have a worse prognosis
• ChT regimens in relapse situations are not standardised and include alkylating agents (cyclophosphamide and high-dose ifosfamide) in combination with
topoisomerase inhibitors (etoposide and topotecan), irinotecan with temozolomide [III, B] or gemcitabine and docetaxel, or high-dose ifosfamide or carbo-
platin with etoposide
High-grade spindle/pleomorphic sarcomas of bone
• Treatment strategies mimic those of OS and include ChT and complete en bloc resection including any soft tissue component
• RT may be considered in inoperable lesions
Chondrosarcoma
• Mesenchymal CS is usually considered to be sensitive to adjuvant or neoadjuvant therapy [IV, C] and is treated using a Ewing-type ChT regimen
• Dedifferentiated CS is often treated as a high-grade bone sarcoma, with systemic and local therapies that need to be adapted to patient’s age [V, C]
• Skull base CSs can be treated with high-dose RT including proton or carbon ion beam RT
• Doxorubicin and ifosfamide may prove active in CS, especially in high-grade lesions, and gemcitabine in combination with docetaxel has also been reported
to be effective
Continued
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evidence and grades of recommendation have been applied using
the system shown in Table 3. Statements without grading were con-
sidered justified standard clinical practice by the experts.
Disclosure
PGC has reported advisory roles for Deciphera Pharmaceuticals,
Eisai, Eli Lilly, Nektar Therapeutics, speaker’s honoraria from
Eisai, Eli Lilly, Pfizer, PharmaMar, and conducted studies spon-
sored by Amgen Dompe´, AROG Bayer, Blueprint Medicines, Eli
Lilly, Daiichi Sankyo Pharma, Epizyme, GlaxoSmithKline,
Novartis, Pfizer, PharmaMar; SBi has reported advisory/consult-
ant roles for Lilly, Bayer, Pfizer, Novartis, Isolfol and Clinigen
and conducted studies sponsored by Janssen-Cilag, Eisai and
Loxo Oncology; SBa has reported research support from
Novartis, Incyte, Blueprint Medicines, has received honoraria or
consultation fees from Novartis, Lilly, Pfizer, PharmaMar and
Bayer; SBi has reported advisory/consultant roles for Lilly, Bayer,
Pfizer, Novartis, Isolfol and Clinigen and conducted studies
sponsored by Janssen-Cilag, Eisai and Loxo Oncology; SBo has
reported honoraria and travel grants from Nanobiotix and Lilly
and received travel grants from PharmaMar; IB has reported re-
search funds from MSD, Bristol-Myers Squibb, Novartis, Roche,
Regeneron, Amgen, Astra-Zeneca, Boehringer Ingelheim and
Genesis and advisory boards, honorarium and travel expenses
from MSD, Bristol-Myers Squibb, Novartis, Roche, Amgen,
Astra-Zeneca, Boehringer Ingelheim, LEO Pharma, Galenica,
Genesis and Sanofi; JVMGB has received a research grant from
Servier and honoraria from Nanobiotix for reviewing cases for
their trial; TB has reported honoraria from Roche and
PharmaMar and advisory board and honoraria from Amgen,
Bayer, Novartis, Eisai and Eli Lilly; JMB has reported consulting
advisory role for PharmaMar, Lilly, Bayer, Novartis and being a
member of the speaker’s bureau for PharmaMar and received
travel grants from PharmaMar and Lilly; EDA has received hono-
raria from PharmaMar, Roche, Lilly and Pfizer and travel grants
from Roche; APDT is a member of the speakers’ bureau for Lilly,
Giant cell tumour of bone
• Treatment options for GCTs include en bloc excision [IV, A] and intralesional curettage with or without adjuvant in carefully selected cases
• Denosumab is standard treatment in unresectable or metastatic GCT [III, A], although its use in the neoadjuvant setting is debated
• RT can provide local control in GCT but can be associated with transformation into a high-grade sarcoma, and should be limited to cases in which surgery
leads to unacceptable morbidity and denosumab is ineffective or contraindicated [IV, D]
Chordoma
• Chordomas are very rare tumours, and management should be carried out at referral centres and/or referral networks with a multidisciplinary team
• En bloc R0 resection is standard treatment [IV, B], if feasible; otherwise, deﬁnitive RT alone should be considered as a valid alternative [V, C]
• For sacral chordoma, surgery should be offered if the chordoma arises from S4 and below or discussed in the context of other alternatives for tumours origi-
nating above S3. Surgery is preferred for tumours originating from S3, especially if the preservation of S2 roots is possible
• R1 surgery plus high-dose RT is the treatment of choice for skull base and upper cervical tract chordoma
• Indications for deﬁnitive RT include unresectable disease, inoperable patients and neurological impairment not accepted by the patient. RT should be con-
sidered in the case of R1 resections
• In the case of local relapse, recommended treatment includes surgery and/or RT and/or systemic treatment
• For oligometastatic disease, surgery/radiofrequency ablations/stereotactic radiation of metastases can be considered in selected cases
• Imatinib or sorafenib may be beneﬁcial in advanced chordoma in terms of progression-free survival and mainly non-dimensional tumour responses
Follow-up, long-term implications and survivorship
• Follow-up of high-grade tumours should include both a physical examination of the tumour site and assessment of the function and possible complications
of any reconstruction. Local imaging and chest X-ray/CT could be a proposed strategy
• A recommended follow-up policy varies among experts and may foresee intervals between checks after the completion of ChT, approximately every
3months for the ﬁrst 2 years; every 6months for years 3–5; every 6–12months for years 5–10, and thereafter every 0.5–2 years
• Chest CT, if used instead of chest X-rays, should be carried out with low-dose, radiation-sparing techniques
• For low-grade bone sarcoma, the frequency of follow-up visits may be lower (e.g. 6months for 2 years and then annually)
• In ES, where osseous metastases are likely, isotope bone scanning can be used in addition to X-ray imaging but should be weighed against the additional ra-
diation exposure
• More modern techniques (e.g. PET or whole-body MRI) are increasingly being adopted into routine practice but require further evaluation in clinical trials
• Long-term toxic effects of ChT, surgery and RT should be evaluated, and monitoring for late effects should be continued for > 10 years after treatment,
depending on the ChT protocol and radiation used
• Long-term cardiac evaluation is important, as it has been shown that deterioration of cardiac function can still occur decades after anthracycline treatment
• Secondary cancers may arise in survivors of bone sarcomas, either related to, or independent of, irradiation. Secondary leukaemia, particularly acute myeloid
leukaemia, may rarely be observed following ChT, as early as 2–5 years after treatment
AP, alkaline phosphatase; BuMel, busulfan and melphalan; ChT, chemotherapy; CS, chondrosarcoma; CT, computed tomography; ES, Ewing sarcoma; GCT,
giant cell tumour; HD-MTX, high-dose methotrexate; LDH, lactate dehydrogenase; MRI, magnetic resonance imaging; OS, osteosarcoma; PET, positron
emission tomography; R0, no tumour at the margin; R1, microscopic tumour at the margin; RT, radiotherapy; S2-S4, sacral spinal nerve 2-4; WHO, World
Health Organization.
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ria from Eli Lilly and PharmaMar, research grants from Amgen
Dompe´, Advenchen, Bayer, Eli Lilly, Daiichi Sankyo Pharma,
Epizyme Inc., Novartis, Pfizer and PharmaMar; travel grants
from PharmaMar and has reported advisory/consultant roles for
Bayer, Eli Lilly, ImmuneDesign, Maxivax and PharmaMar;
WVdG has received research grants from Novartis; EW has
reported travel/research grants and/or honoraria from Novartis
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Table 3. Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health Service
Grading Systema)
Levels of evidence
I Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-analyses of
well-conducted randomised trials without heterogeneity
II Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or
of trials with demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts opinions
Grades of recommendation
A Strong evidence for efﬁcacy with a substantial clinical beneﬁt, strongly recommended
B Strong or moderate evidence for efﬁcacy but with a limited clinical beneﬁt, generally recommended
C Insufﬁcient evidence for efﬁcacy or beneﬁt does not outweigh the risk or the disadvantages (adverse events, costs, . . .), optional
D Moderate evidence against efﬁcacy or for adverse outcome, generally not recommended
E Strong evidence against efﬁcacy or for adverse outcome, never recommended
aBy permission of the Infectious Diseases Society of America [123].
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